McLean succeeds Craig Cordola in the role, which has been restructured to sharpen focus on operational execution and accountability across the company's worldwide clinic network. Since joining the organization in August 2025, she has been credited with implementing new management tools and strengthening talent within the U.S. clinic division. Michael Sen, Chairman of the Supervisory Board, cited her deep dialysis expertise and leadership as key factors in the appointment, noting the board's confidence in her ability to accelerate progress within the segment.
In section Releases
Fresenius Medical Care Appoints Cassie McLean to Management Board
The Supervisory Board of Fresenius Medical Care has named Cassie McLean as the new CEO of its Care Delivery segment, effective August 1, 2026. McLean, who previously led Fresenius Kidney Care, joins the company's management board to oversee the global clinic business and drive the firm's ongoing performance strategy.
Prior to her tenure at Fresenius, McLean served as CEO of the behavioral health firm Monte Nido and spent nearly 16 years at DaVita Kidney Care in various leadership capacities. Her background includes a Master of Public Administration in Healthcare Finance from New York University. In her new capacity, McLean will lead the execution of the FME Reignite strategy, with a primary focus on improving treatment growth and ensuring sustainable profitability across the firm’s international care delivery operations.
Comments (0)
No comments yet. Be the first!